



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-063001	Application No. 10/086,217
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.99(b))		Applicant Mundy et al.	
		Filing Date February 21, 2002	Group Art Unit 1644

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AF							
	AG							
	AH							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
<i>MH</i>	AI	Damiano et al., "Integrin-Mediated Drug Resistance in Multiple Myeloma", 2000, Leukemia and Lymphoma, vol. 38 (1-2):71-81
<i>MH</i>	AJ	Damiano et al., "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins", March 1, 1999, Blood, vol. 93(5):1658-1667
<i>MH</i>	AK	Mundry et al., "Stromal cells regulate survival of B-lineage leukemic cells", Sept. 1, 2000, Blood, vol. 96 (5):1926-1932

Examiner Signature <i>Maker Hadland</i>	Date Considered <i>10/27/04</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
A061CIP2SERIAL NO.
10/086,217APPLICANT
Gregory R. Mundy and
Toshiyuki YonedaCONFIRMATION NO.
5114FILING DATE
February 21, 2002GROUP
1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
<i>ms</i>	Alsina, M. et al., "Development of an In Vivo Model of Human Multiple Myeloma Bone Disease," <u>BLOOD</u> 87: 1495-1501 (1996).
<i>ms</i>	Altal, M. et al., "A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma," <u>N ENGL J MED</u> 335: 91-97 (1996).
<i>ms</i>	Atkins, C., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," <u>N ENGL J MED</u> 335: 1844 (1996).
<i>ms</i>	Oivanen, T. M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," <u>N ENGL J MED</u> 335: 1844-1845 (1996).
<i>ms</i>	Altal, M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma - In Reply," <u>N ENGL J MED</u> 335: 1844-1845 (1996).
<i>ms</i>	Barlogie, B. et al., "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients," <u>BLOOD</u> 98: 492-494 (2001).
<i>ms</i>	Bataille, R. et al., "Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," <u>J CLIN INVEST</u> 84: 2008-2011 (1989).
<i>ms</i>	Bataille, R. et al., "Mechanisms of Bone Lesions in Multiple Myeloma," <u>HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA</u> 6: 285-295 (1992).
<i>ms</i>	Bataille, R. et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," <u>BLOOD</u> 86: 685-691 (1995).
<i>ms</i>	Berenson, J. R. et al., "Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events," <u>J CLIN ONCOL</u> 16: 593-602 (1998).
<i>ms</i>	Seymour, J. F., "Correspondence: Long-Term Pamidronate in Multiple Myeloma," <u>J CLIN ONCOL</u> 16: 2572 (1998).
<i>ms</i>	Berenson, J. R., "Correspondence: Long-Term Pamidronate in Multiple Myeloma - In Reply," <u>J CLIN ONCOL</u> 16: 2572-2573 (1998).
<i>ms</i>	Boyce, B. F. et al., "Boilus Injections of Recombinant Human Interleukin-1 Cause Transient Hypocalcemia in Normal Mice," <u>ENDOCRINOLOGY</u> 125: 2780-2783 (1989).
<i>ms</i>	Chauhan, D. et al., "Regulation of Interleukin 6 in Multiple Myeloma and Bone Marrow Stromal Cells," <u>STEM CELLS</u> 13 (suppl 2): 35-39 (1995).
<i>ms</i>	Dallas, S. L. et al., "Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease," <u>BLOOD</u> 93: 1697-1706 (1999).

EXAMINER

Maher Haddad

DATE CONSIDERED

10/27/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
		FILING DATE February 21, 2002	GROUP 1644



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
mh	Epstein, J., "Myeloma Phenotype: Clues To Disease Origin and Manifestation," <u>HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA</u> 6:249-256 (1992).
mh	Garrett, I. R. et al., "A Murine Model of Human Myeloma Bone Disease," <u>BONE</u> 20: 515-520 (1997).
mh	Gossilar, U. et al., "Predominant Role of α 4-integrins for distinct steps of lymphoma metastasis," <u>Proc. Natl. Acad. Sci. USA</u> 93: 4821-4826 (1996).
mh	MacDonald, B. R. et al., "Effects of Human Recombinant CSF-GM and Highly Purified CSF-1 on the Formation of Multinucleated Cells with Osteoclast Characteristics in Long-Term Bone Marrow Cultures," <u>J BONE AND MINERAL RESEARCH</u> 1: 227-233 (1986).
mh	Matsuura, N. et al., "Induction of Experimental Bone Metastasis in Mice by Transfection of Integrin α 4 β 1 into Tumor Cells," <u>AM J PATHOL</u> 148: 55-61 (1996).
MH	Michigami, T. et al., "Interactions of Myeloma Cells with Bone Marrow Stromal Cells Via α 4 β 1 Integrin-VCAM-1 Is Required For the Development of Osteolysis," <u>Nineteenth Annual Meeting of the American Society for Bone and Mineral Research</u> , Cincinnati, Ohio: Abstract 104 (9/14/1997); <u>J. BONE AND MINERAL RESEARCH</u> 12 Supplement: p. S218 (1997).
mh	Michigami, T. et al., "Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α 4 β 1-integrin enhances production of osteoclast-stimulating activity," <u>BLOOD</u> 96: 1953-1960 (2000).
mh	Mittelman, M. et al., "Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models," <u>Proc. Natl. Acad. Sci. USA</u> 98: 5181-5186 (2001).
mh	Mori, Y. et al., "Anti- α 4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-Marrow Stromal Cell Interactions," <u>Twenty-First Annual Meeting of the American Society for Bone and Mineral Research</u> , St. Louis, Missouri: Abstract 1161 (10/3/1999); <u>J. BONE AND MINERAL RESEARCH</u> 14 Supplement 1: p. S148 (1999).
MH	Mundy, G. R. and Bertolini, D. R., "Bone Destruction and Hypercalcemia in Plasma Cell Myeloma," <u>SEMINARS IN ONCOLOGY</u> 13: 291-299 (1986).
MH	Mundy, G. R., "Myeloma Bone Disease," <u>EURO J CANCER</u> 34: 246-251 (1998).
MH	Oyajobi, B. O. et al., "Expression of Rank Ligand (Rankl) By Myeloma Cells Requires Binding To Bone Marrow Stromal Cells Via An α 4 β 1-VCAM-1 Interaction," <u>Second Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society</u> , San Francisco, California: Abstract 1133 (12/4/1998); <u>BONE</u> 23(5 Supplement): p. S180 (1998).
mh	Papayannopoulou, T. and Nakamoto, B., "Peripheralization of hemopoietic progenitors in primates treated with anti-VLA ₄ integrin," <u>Proc. Natl. Acad. Sci. USA</u> 90: 9374-9378 (1993).
mh	Qian, F. et al., "Expression of the Integrin α 4 β 1 on Melanoma Cells Can Inhibit the Invasive Stage of Metastasis Formation," <u>CELL</u> 77: 335-347 (1994).

EXAMINER

Maher Haddad

DATE CONSIDERED

10/27/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
		FILING DATE February 21, 2002	GROUP 1644



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
m t	Shimizu, N. et al., "Disruption of Cell-Cell Contact with Stromal Cells Using Anti- α 4integrin Antibody Enhances Sensitivity of Myeloma Cells to Melphalan in Vitro and in Vivo," <u>Twenty-Third Annual Meeting of the American Society for Bone and Mineral Research, Phoenix, Arizona: Presentation Number SU078 (10/14/2001)</u> .
m H	Tinhofer, I. et al., "Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma," <u>BLOOD 95: 610-618 (2000)</u> .
m H	Vanderkerken, K. et al., "Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse," <u>BRIT J CANCER 76: 451-460 (1997)</u> .

EXAMINER

Maken Haddad

DATE CONSIDERED

10/27/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.